Global Atopic Eczema Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Atopic Eczema Treatment Market is presumed to reach the market size of nearly USD 21.19 BN by 2030 from USD 11.29 BN in 2022 with a CAGR of 8.19% under the study period 2023 - 2030.

Atopic eczema or atopic dermatitis is a persistent skin condition marked by dry, pruritic (itchy), and inflamed skin. Treatment for atopic eczema aims to alleviate symptoms, reduce inflammation, and prevent flare-ups.

MARKET DYNAMICS

Increasing incidences of atopic eczema worldwide prompt a rising demand for effective treatments. Ongoing research and development initiatives continuously introduce innovative therapies, including advanced drug delivery systems and biologics, enhancing treatment efficacy. Technological advancements further enable the creation of more patient-friendly solutions. Rising healthcare expenditure globally allows broader access to advanced treatments, while heightened awareness among patients and healthcare providers leads to early diagnosis and treatment initiation. Supportive government policies and funding for research encourage the development of more therapies, fostering market growth. Additionally, a competitive market landscape encourages pharmaceutical innovation, resulting in a wider array of treatment options. Moreover, the trend toward personalized medicine and tailored treatments based on individual patient characteristics drives the creation of more targeted therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of atopic eczema treatment. The growth and trends of atopic eczema treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the atopic eczema treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Biologics
PDE4 Inhibitors

By Route Of Administration

Topical
Injectable
Oral

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Atopic Eczema Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Atopic Eczema Treatment market include Pfizer Inc., AbbVie Inc., GALDERMA LABORATORIES, L.P., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Sanofi, Novartis AG, Eli Lilly and Company (Dermira), LEO Pharma Inc., and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112987

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ATOPIC ECZEMA TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Biologics Historic and Forecast Sales by Regions
5.5 PDE4 Inhibitors Historic and Forecast Sales by Regions

6 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1 Overview by Route of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Route of Administration
6.4 Topical Historic and Forecast Sales by Regions
6.5 Injectable Historic and Forecast Sales by Regions
6.6 Oral Historic and Forecast Sales by Regions

7 . GLOBAL ATOPIC ECZEMA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ATOPIC ECZEMA TREATMENT COMPANIES

8.1. Atopic Eczema Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ATOPIC ECZEMA TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. AbbVie Inc.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GALDERMA LABORATORIES L.P.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Otsuka Pharmaceutical Co. Ltd.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Regeneron Pharmaceuticals Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Incyte Corporation
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Sanofi
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Novartis AG
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Eli Lilly and Company (Dermira)
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. LEO Pharma Inc
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Others
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies